View CLICK HERE TO REGISTER REGISTER
PROGRAM OVERVIEW

Listen to Dr Rutland discuss RSV and the impact it can have on the adult population 60 years of age and older. He will also share details about AREXVY, the vaccine recently FDA approved to protect against RSV-associated lower respiratory tract disease (LRTD) in individuals 60 years of age or older.

PROGRAM OBJECTIVES
  • Review the RSV disease burden and unmet need in older adults
  • Introduce AREXVY and key data from the clinical trial
INTENDED AUDIENCE

This broadcast is intended for US healthcare professionals.

{REMOTELIVEEVENTS}
Broadcast Schedule

The broadcast will be available at various times throughout the day, depending on your time zone. Reference the chart below for a complete list of broadcast times.

You may participate in any or all webcast sessions.

Available via

  • Webcast
  • Webcast
  • Tablet
  • Mobile

Broadcast Date: Tuesday, June 13, 2023

EASTERN CENTRAL MOUNTAIN PACIFIC
12:15 PM 11:15 AM 10:15 AM 9:15 AM
1:15 PM 12:15 PM 11:15 AM 10:15 AM
2:15 PM 1:15 PM 12:15 PM 11:15 AM
3:15 PM 2:15 PM 1:15 PM 12:15 PM

Indication for AREXVY

AREXVY is indicated for active immunization for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus in individuals 60 years of age and older.

Important Safety Information for AREXVY
  • AREXVY is contraindicated in anyone with a history of a severe allergic reaction (eg, anaphylaxis) to any component of AREXVY
  • Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of AREXVY
  • Syncope (fainting) may occur in association with administration of injectable vaccines, including AREXVY. Procedures should be in place to avoid injury from fainting
  • Immunocompromised persons, including those receiving immunosuppressive therapy, may have a diminished immune response to AREXVY
  • The most commonly reported adverse reactions (≥10%) were injection site pain (60.9%), fatigue (33.6%), myalgia (28.9%), headache (27.2%), and arthralgia (18.1%)
  • Vaccination with AREXVY may not result in protection of all vaccine recipients

Please see full Prescribing Information for AREXVY.

Trademarks are property of their respective owners.